6-K ·Filed Jul 17, 2026

QTEX

QTREX Quantum Ltd.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001185185-26-003004
Notable filing: 6-K
Actionable Insight • Neutral

This is a minor positive signal for QTREX's AME strategy, adding relevant technical expertise to the board. However, the appointment does not change near-term fundamentals. Monitor for commercial production milestones or additional board/management changes that could signal progress toward revenue generation.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
QTEX ▼ -22.84% at T+20d
NEUTRAL call ✗ call lost -22.84% · α vs SPY -27.29% · entry $1.27 → $0.9799
Next anchor: T+60d in 9d
Latest observation: T+54 -82.75% FF3 residual α
Entry anchored
Jul 17, 04:47 AM ET
via exchange tick
T+1d
-6.30%
call -6.30% · α -6.14%
$1.19
settled 3mo ago
T+5d
-30.28%
call -30.28% · α -29.59%
$0.8855
settled 2mo ago
T+20d
-22.84%
call -22.84% · α -27.29%
$0.9799
settled 7w ago
T+60d
—
call — · α —
—
in 9d

Price Chart

Loading chart...

Executive Summary

QTREX Quantum Ltd. appointed Dr. Shlomit Chappel-Ram, a former VP of R&D at Nano Dimension Ltd., as an independent director effective July 14, 2026. The appointment adds direct AME (additively manufactured electronics) operating experience to the board as the company advances its quantum connectivity platform following its acquisition of the AME technology from Nano Dimension in April 2026. This is a routine board change with no material financial impact.

Key Facts

  • Dr. Shlomit Chappel-Ram appointed as independent director effective July 14, 2026.
  • She previously served as VP of R&D at Nano Dimension Ltd. (Nasdaq: NNDM), the source of QTREX's AME platform.
  • QTREX acquired the AME platform from Nano Dimension in April 2026.
  • No compensation or financial terms disclosed for the appointment.

Financial Impact

No financial impact — routine board appointment with no disclosed compensation or material terms.

Risk Factors

  • No new risks identified; the company remains pre-revenue with ongoing development-stage execution risk.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001185185-26-003004
Document: qtrexex99-1.htm0001185185-26-003004
Document: 0001185185-26-003004-index-headers.html0001185185-26-003004
Document: 0001185185-26-003004-index.html0001185185-26-003004
Document: 0001185185-26-003004.txt0001185185-26-003004
19 reports for QTEX
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+60▲ +53.16%Jun 17, 2026
Filters
Rows
Reports for QTEX — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
6-K
BULLISH ★ 7/10
$0.8160 $0.6820▼ −16.42%▼ −16.34%$1.10 (+34.80%)
Aug 21, 2026
6w ago
424B5
BEARISH ★ 6/10
$0.9155 $0.8564▲ +6.46%▲ +5.93%$1.10 (−20.15%)
Aug 19, 2026
6w ago
6-K
NEUTRAL ★ 4/10
$1.12 $0.8702▼ −22.30%▼ −20.35%$1.10 (−1.79%)
Aug 3, 2026
8w ago
6-K
NEUTRAL ★ 4/10
$1.01 $0.8273▼ −18.09%▼ −19.33%$1.10 (+8.91%)
Jul 31, 2026
9w ago
Press Release
NEUTRAL ★ 4/10
$0.9000 $0.8340▼ −7.33%▼ −10.32%$1.10 (+22.22%)
Jul 24, 2026
10w ago
6-K
NEUTRAL ★ 5/10
$0.9497 $0.8664▼ −8.77%▼ −12.07%$1.10 (+15.83%)
Jul 22, 2026
10w ago
Press Release
MIXED ★ 5/10
$0.9060 $1.12▲ +23.62%▲ +20.72%$1.10 (+21.41%)
Jul 17, 2026
11w ago
6-K
NEUTRAL ★ 2/10
$1.27 $0.9799▼ −22.84%▼ −27.29%$1.10 (−13.39%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 2/10
$1.27 $0.9799▼ −22.84%▼ −27.29%$1.10 (−13.39%)
Jul 14, 2026
11w ago
6-K
BULLISH ★ 5/10
$1.50 $0.9959▼ −33.61%▼ −36.10%$1.10 (−26.67%)
Showing 10 of 19

US Market Status

Market Closed — Opens Mon (56h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access